Welcome to our dedicated page for Enlivex Therapeutics SEC filings (Ticker: ENLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enlivex Therapeutics Ltd. (ENLV) files its regulatory reports with the U.S. Securities and Exchange Commission as a foreign private issuer, and these SEC filings provide detailed insight into the company’s clinical operations and digital asset treasury strategy. On this page, you can review Enlivex Form 6-K reports covering topics such as the ENX-CL-05-001 Phase I/II trial of Allocetra™ in moderate-to-severe knee osteoarthritis, including three- and six-month topline data, as well as shareholder letters discussing the company’s strategic roadmap for Allocetra™ and knee osteoarthritis development.
Filings also document Enlivex’s capital markets and treasury activities. Recent Form 6-K submissions describe a large private placement of ordinary shares and pre-funded warrants, the associated securities purchase agreement and registration rights agreement, and the intended use of proceeds to implement a digital asset treasury strategy centered on the RAIN token. Additional exhibits outline a treasury management agreement for handling digital asset accounts, a shareholders’ agreement with lock-up and voting provisions, and an exclusive option agreement with the RAIN foundation to purchase RAIN tokens within a specified period.
Corporate governance and shareholder matters appear in filings related to annual and extraordinary general meetings, including notices, proxy statements, and voting outcomes. Financial statement packages and operating and financial review and prospects are furnished on Form 6-K for interim periods, providing unaudited condensed consolidated financial information and management discussion. Through this filings page, users can access Enlivex’s SEC-reported information in one place, while AI-powered tools can help summarize lengthy documents, highlight key terms of financing and treasury agreements, and surface clinical and risk factor disclosures that are most relevant to ENLV’s business in macrophage reprogramming immunotherapy and its RAIN-focused digital asset treasury policy.
Enlivex Therapeutics reports that its primary digital treasury asset, the RAIN token, was listed on the KuCoin cryptocurrency exchange effective January 6, 2026. KuCoin is described as a major global platform with more than 40 million users and deep retail liquidity, and the listing is expected to expand market access and secondary liquidity for RAIN.
Management views exchange listings as important milestones for its digital asset treasury strategy, which is centered on holding RAIN as Enlivex’s main treasury reserve asset. Alongside this strategy, Enlivex continues to operate a biopharmaceutical business developing Allocetra™, a late-stage therapy candidate for osteoarthritis, a highly prevalent and disabling joint disease affecting tens of millions of people in the United States and hundreds of millions worldwide.
Enlivex Therapeutics Ltd. reported that it has scheduled an Extraordinary General Meeting of Shareholders. The meeting will take place on February 3, 2026, at 7:00 p.m. Israel time at the company’s offices at 14 Einstein Street, Nes Ziona, Israel.
The company has prepared a notice, proxy statement and proxy card for this meeting, which are included as exhibits to this report and incorporated by reference into several existing registration statements on Forms S-8 and F-3. Shareholders can use the proxy materials to review the matters to be voted on and to submit their voting instructions.
Enlivex Therapeutics Ltd. (ENLV) reported the closing of a significant private placement, issuing 212,000,000 ordinary shares or pre-funded warrants at $1.00 per share or $0.99 per pre-funded warrant, raising $212.0 million in gross proceeds. The company plans to use substantially all net proceeds to purchase RAIN and to establish cryptocurrency treasury operations as part of its digital asset treasury strategy, as well as to cover related transaction fees and expenses.
The securities, including additional Lead Investor Warrants for 1,750,000 shares issued to Sobrinia Ltd., were sold under exemptions from SEC registration. In connection with the deal, director Andrew Singer resigned and was replaced on the Audit Committee by Dr. Roger Pomerantz, who is designated as an audit committee financial expert. Matteo Renzi joined the board as a director, serving until the 2026 annual general meeting.
Enlivex Therapeutics (ENLV) reported a large financing and a major shift in how it will manage its capital. The company entered a private placement for 212,000,000 ordinary shares, or pre-funded warrants, at $1.00 per share or $0.999 per pre-funded warrant, with proceeds earmarked largely to build a digital asset treasury centered on RAIN tokens, plus stablecoins and other short-duration digital assets, to support ongoing operations and the RAIN ecosystem.
Pre-funded warrants are immediately exercisable at $0.001 per share with a 9.99% beneficial ownership cap, and investors receive resale registration rights. A shareholders’ agreement imposes staged lock-ups and provides for a warrant to buy 1,750,000 shares at $1.00 for Sobrinia Ltd. The company also adopted an ATM program of up to $299,553,108 of shares under its F-3 shelf, signed a three-year treasury management agreement for digital assets, obtained an option to buy up to $918.0 million of RAIN tokens (not using private placement proceeds), and accelerated vesting of all outstanding employee and executive equity awards at closing.
Enlivex Therapeutics Ltd. has launched an at-the-market equity program to sell up to $299,553,108 of ordinary shares through BTIG on Nasdaq or other U.S. markets. Net proceeds are intended mainly for acquiring RAIN governance tokens and building a new digital asset treasury business, alongside working capital and ongoing clinical, regulatory, manufacturing and R&D activities.
The company plans to concentrate its treasury in RAIN and use staking and DeFi strategies while relying on third-party custodians, exposing it to significant crypto price, liquidity, regulatory and cybersecurity risks. Enlivex continues its macrophage reprogramming program, reporting positive Phase IIa six‑month data in knee osteoarthritis patients aged 60+ with clinically meaningful pain and function improvements versus placebo. Recent actions also include a large private placement of 212,000,000 shares or pre-funded warrants at about
Enlivex Therapeutics Ltd. (ENLV) filed a Form 6-K reporting that it has released six-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled trial of its Allocetra™ therapy in patients with moderate-to-severe knee osteoarthritis. The company furnished a detailed press release and an investor presentation as exhibits to this report. Selected topline data from the press release and key slides from the investor presentation are also incorporated by reference into several of Enlivex’s existing registration statements on Forms S-8 and F-3, linking these new clinical results to documents that can support potential future securities offerings.
Enlivex Therapeutics Ltd. (ENLV) reported that it held its 2025 Annual General Meeting of Shareholders on November 17, 2025. Shareholders voted on proposals described in the earlier notice and proxy statement, and each proposal was approved by the required majority. The company also stated that this report is incorporated by reference into its existing registration statements on Forms S-8 and F-3, which helps keep those filings updated with its latest corporate actions.
Enlivex Therapeutics Ltd. reported that its 2025 Annual General Meeting of Shareholders was convened but adjourned due to a lack of quorum. The meeting will reconvene on November 17, 2025 at 7:00 p.m. Israel time at the company’s offices in Nes Ziona, Israel.
Voting deadlines were extended: mailed proxies are due by November 14, 2025 at 7:00 p.m. Israel time, and telephone or internet voting is open until November 13, 2025 at 11:59 p.m. Eastern time. Shareholders holding through the Tel Aviv Stock Exchange may vote in person with an Ownership Certificate, by proxy with an Ownership Certificate delivered by November 13, 2025 at 7:00 p.m. Israel time, or electronically via the Israel Securities Authority system until 1:00 p.m. Israel time on November 17, 2025.
Enlivex Therapeutics Ltd. filed a Form 6-K to report its Annual General Meeting of Shareholders is scheduled for November 10, 2025 at 7:00 p.m. Israel time at the company's offices, 14 Einstein Street, Nes Ziona, Israel. The report states that the meeting notice, proxy statement and a form of proxy card are attached as Exhibit 99.1 and Exhibit 99.2 and are incorporated by reference into the report. The filing is signed by CEO Oren Hershkovitz.
FAQ
What is the current stock price of Enlivex Therapeutics (ENLV)?
What is the market cap of Enlivex Therapeutics (ENLV)?
